Floatz logo

AN ADENOVIRUS VECTOR CANCER VACCINE COMPOSED OF A REPLICATION-DEFECTIVE, SER OTYPE 5 ADENOVIRUS (AD5) THAT HAS BEEN MODIFIED BY REMOVAL OF THE E1, E2B AND E3 GENES AND INSERTION OF A MODIFIED HUMAN BRACHYURY PROTEIN-EXPRESSING GENE

Colorectal Cancer Metastatic

ImmunityBio, Inc.vaccinePhase 1/2Dormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
18/ 100
Competitive Position
65/ 100

Competitive context

65 Active assets in the Colorectal Cancer Metastatic cohort.

Asset / SponsorPhaseRating
Binimetinib
Pierre Fabre Medicament
Phase 3BB
Irinotecan
Oncolytics Biotech
Phase 4BB
Aflibercept
Sanofi
Phase 3BB
Inno-206
Northwell Health
Phase 4B
Durvalumab
University of Iowa
Phase 2B

View all 50 →

Same molecule, other indications

AN ADENOVIRUS VECTOR CANCER VACCINE COMPOSED OF A REPLICATION-DEFECTIVE, SER OTYPE 5 ADENOVIRUS (AD5) THAT HAS BEEN MODIFIED BY REMOVAL OF THE E1, E2B AND E3 GENES AND INSERTION OF A MODIFIED HUMAN BRACHYURY PROTEIN-EXPRESSING GENE is also rated in:

triple-negative breast carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
malignant pancreatic neoplasmDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →